Cancer risk with salmon calcitonin

Medical Letter on Drugs and Therapeutics

Volumn 55, Issue 1414, 2013, Pages 29-

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; PLACEBO; SALCATONIN;

CANCER RISK; DISEASE ASSOCIATION; HUMAN; NOTE; POSTMENOPAUSE OSTEOPOROSIS;

EID: 84876221088     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (3)

1. Drugs for postmenopausal osteoporosis. Treat Guidel Med Lett 2011; 9:67.
2. Novartis. FDA Joint Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee meeting on the benefit/risk of salmon calcitonin for the treatment of postmenopausal osteoporosis. Briefing book. Available at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341781.pdf. Accessed April 4, 2013.
3. CH Chesnut 3rd et al. A randomized trial of nasal spray salmon calci-tonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000; 109:267.